EFI
ASBPW

EHP Funds Inc’s Aspire Biopharma Warrant ASBPW Stock Holding History

EHP Funds Inc’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$753 – 152
2024
Q1 		$753 Hold
25,000
– – ﹤0.01% 172
2023
Q4 		$1.5K Hold
25,000
– – ﹤0.01% 184
2023
Q3 		$1.27K Hold
25,000
– – ﹤0.01% 259
2023
Q2 		$1.25K Buy
+25,000
New +$918 ﹤0.01% 287

Other funds holding ASBPW

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EHP Funds Inc's ASBPW Position: Q2 2024 in Review

EHP Funds Inc sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2024, closing a stake of 25,000 shares — an estimated $753 sold.

EHP Funds Inc first reported a position in ASBPW in Q2 2023 and held it in 4 quarters. The position peaked at $1.5K in Q4 2023. 33 funds tracked by Wall St. Rank hold ASBPW as of Q2 2024.

  • EHP Funds Inc reported no remaining Aspire Biopharma Warrant position as of Q2 2024 after selling out during the quarter.
  • EHP Funds Inc sold 25,000 Aspire Biopharma Warrant shares in Q2 2024, an estimated $753.
  • EHP Funds Inc first reported a position in Aspire Biopharma Warrant in Q2 2023 and held it in 4 quarters.
  • EHP Funds Inc's Aspire Biopharma Warrant position peaked at $1.5K in Q4 2023.
  • 33 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2024.

Based on EHP Funds Inc's 13F filing for Q2 2024, filed 14 Aug 2024.